Quick Facts at a Glance
- Recall Date
- February 12, 2026
- Hazard Level
- HIGH
- Brands
- EPTIFIBATIDE, Slate Run Pharmaceuticals, LLC
- Category
- Health & Personal Care
- Sold At
- Multiple Retailers
- Geographic Scope
- 1 states
- At-Risk Groups
- GENERAL
What to Do Now
Use this page like a recall checklist: verify the product first, then act on the official remedy.
Immediate steps
- 1Stop using the product until you confirm whether it is included in the recall.
- 2Compare the product label, model number, UPC, color, size, and purchase location against the identifiers below.
- 3Follow the official remedy from FDA - Drug Safety; save photos, receipts, labels, and correspondence before contacting the company.
- 4If the product could harm a child, older adult, pet, or patient, move it out of reach immediately.
Check these identifiers
- Brand
- EPTIFIBATIDE, Slate Run Pharmaceuticals, LLC
- Product type
- Eptifibatide Injection
- Model numbers
- All lots within expiry
- UPC codes
- 70436-026, 70436-027, 70436-162, 70436-163, 70436-026-80, 70436-027-80, 70436-162-80, 70436-163-80
- Sold at
- Multiple Retailers
- Where affected
- ALL
Recall Timeline
Key dates and source checks for this recall record.
Recall announced
February 12, 2026
Reported by FDA DRUG
March 4, 2026
RecallRadar source check
March 11, 2026
Consumer action
Use the official remedy and keep documentation.
Hazard Information
Labeling: Not Elsewhere Classified. The carton for Eptifibatide Injection 75 mg/100 mL states 75 mg/100 mL vial for weight-adjusted bolus dosing. The approved statement is 75 mg/100 mL vial for weight-adjusted infusion.
What You Should Do
Consumers and healthcare providers should stop using this product immediately. Contact Slate Run Pharmaceuticals or your healthcare provider for guidance. Notification method: Letter
About This Product
Eptifibatide Injection is a medication used in healthcare settings as an anticoagulant. It is typically administered intravenously during procedures to prevent blood clots.
Why This Is Dangerous
The product's labeling error can lead to incorrect dosing, which may affect patient safety during treatment. Administering a bolus dose instead of an infusion can lead to serious complications.
Industry Context
This recall is not part of a broader industry pattern.
Real-World Impact
Consumers must stop using the product immediately, which could impact treatment plans for patients. The urgency to correct the labeling can lead to temporary disruptions in care.
Practical Guidance
How to identify if yours is affected
- Check the product packaging for NDC numbers.
- Verify if the vial states 'bolus dosing' instead of 'infusion.'
- Look for expiration dates on the product.
Where to find product info
The NDC numbers can be found on the carton label or the product packaging itself.
What timeline to expect
Expect a timeline of 4-6 weeks for refund processing after returning the product.
If the manufacturer is unresponsive
- Contact the FDA for further assistance.
- Document your communication attempts with Slate Run Pharmaceuticals.
- File a complaint with the FDA if necessary.
How to prevent similar issues
- Always check product labels before use.
- Verify dosing instructions with a healthcare provider.
- Stay informed about recalls through FDA notifications.
Documentation advice
Keep records of your purchase, correspondence with the manufacturer, and photographs of the product for your records.
Get instant alerts for Health & Personal Care recalls
Be the first to know. Free instant alerts to your inbox.
Key Facts
- Recall date: February 12, 2026
- Reported date: March 4, 2026
- Class III recall status
- Nationwide distribution in the USA
Browse More Recalls
Safety Guide
Not sure what to do next? Our guide walks you through the process step by step.
Read: What to Do When You Find a Recalled ProductGet Alerts for Health & Personal Care Recalls
Get instant alerts for recalls that affect you. Free forever.
